Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension

Combined inhibition of NEP (neutral endopeptidase) and ACE (angiotensin-converting enzyme), without unwanted effects, remains an attractive therapeutic strategy in cardiovascular medicine. Omapatrilat, a dual NEP inhibitor–ACE inhibitor, was a promising antihypertensive drug but failed in trials due...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves-Lopes, Rhéure, Montezano, Augusto C., Neves, Karla B., Harvey, Adam, Rios, Francisco J., Skiba, Dominik S., Arendse, Lauren B., Guzik, Tomasz J., Graham, Delyth, Poglitsch, Marko, Sturrock, Edward, Touyz, Rhian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357049/
https://www.ncbi.nlm.nih.gov/pubmed/34304582
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357049/
https://www.ncbi.nlm.nih.gov/pubmed/34304582
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17041

Ejemplares similares